Genmab A/S (NASDAQ:GMAB) Hits New 1-Year Low – Here’s Why

Shares of Genmab A/S (NASDAQ:GMAB) reached a new 52-week low during trading on Monday . The stock traded as low as $18.87 and last traded at $18.99, with a volume of 103803 shares changing hands. The stock had previously closed at $19.00.

Wall Street Analysts Forecast Growth

GMAB has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Down 1.6 %

The stock has a market capitalization of $12.38 billion, a price-to-earnings ratio of 18.18, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. The business has a 50 day simple moving average of $20.84 and a 200-day simple moving average of $23.37.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its position in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares in the last quarter. Cromwell Holdings LLC grew its position in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after buying an additional 2,496 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of Genmab A/S in the fourth quarter worth $93,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.